Phase II data on micafungin [FK463] were presented recently at the 22nd International Congress of Chemotherapy [Amsterdam, The Netherlands; July 2001] showing that this novel antifungal is highly effective in the treatment of oropharyngeal and oesophageal candidiasis in patients with AIDS. Summary data on over 1300 patients indicate an excellent tolerability profile, with a maximum tolerated dose of 8 mg/kg in adults.